Equities analysts expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to post sales of $27.19 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Sangamo Therapeutics’ earnings. The lowest sales estimate is $25.00 million and the highest is $28.00 million. Sangamo Therapeutics posted sales of $57.76 million during the same quarter last year, which would indicate a negative year over year growth rate of 52.9%. The business is scheduled to announce its next earnings results on Wednesday, November 3rd.
On average, analysts expect that Sangamo Therapeutics will report full year sales of $112.38 million for the current financial year, with estimates ranging from $109.81 million to $121.00 million. For the next fiscal year, analysts forecast that the business will report sales of $130.88 million, with estimates ranging from $69.00 million to $307.20 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). The firm had revenue of $27.87 million for the quarter, compared to the consensus estimate of $29.72 million. Sangamo Therapeutics had a negative net margin of 98.21% and a negative return on equity of 27.99%.
Shares of NASDAQ:SGMO opened at $9.28 on Tuesday. Sangamo Therapeutics has a 12 month low of $8.90 and a 12 month high of $19.43. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -9.77 and a beta of 1.66. The company has a 50-day moving average price of $9.79 and a 200-day moving average price of $10.85.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG3 Management LLC bought a new position in Sangamo Therapeutics in the second quarter worth approximately $30,000. Rockefeller Capital Management L.P. raised its position in Sangamo Therapeutics by 2,900.0% in the first quarter. Rockefeller Capital Management L.P. now owns 3,000 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,900 shares during the period. Captrust Financial Advisors raised its position in Sangamo Therapeutics by 31.5% in the first quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,173 shares during the period. Acadian Asset Management LLC raised its position in Sangamo Therapeutics by 48.5% in the first quarter. Acadian Asset Management LLC now owns 9,925 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 3,240 shares during the period. Finally, Prudential Financial Inc. bought a new position in Sangamo Therapeutics in the second quarter worth approximately $133,000. Institutional investors and hedge funds own 52.41% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.
Featured Article: Understanding Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.